The androgen receptor (AR) plays a critical role as a driver of castration-resistant prostate cancer (CRPC). Our previous studies demonstrated that disruption of transforming growth factor-b (TGF-b) signaling via introduction of dominant-negative transforming growth factor-b type II receptor (DNTGFbRII) in the prostate epithelium of transgenic adenocarcinoma of the prostate mice accelerated tumor. This study investigated the consequences of disrupted TGF-b signaling on prostate tumor growth under conditions of castration-induced androgen deprivation in the preclinical model of DNTGFbRII. Our results indicate that in response to androgen deprivation therapy (ADT) the proliferative index in prostate tumors from DNTGFbRII mice was higher compared with prostate tumors from TGFbRII wild-type (WT) mice, whereas there was a reduced incidence of apoptosis in tumors from DNTGFbRII. Protein and gene expression profiling revealed that tumors from DNTGFbRII mice exhibit a strong nuclear AR localization among the prostate tumor epithelial cells and increased AR messenger RNA after ADT. In contrast, TGFbRII WT mice exhibited a marked loss in nuclear AR in prostate tumor acini (20 weeks), followed by a downregulation of AR and transmembrane protease serine 2 messenger RNA. There was a significant increase in nuclear AR and activity in prostate tumors from castrate DNTGFbRII compared with TGFbRII WT mice. Consequential to aberrant TGF-b signaling, ADT enhanced expression and nuclear localization of Smad4 and b-catenin. Our findings support that under castrate conditions, aberrant TGF-b signaling leads to AR activation and b-catenin nuclear localization, an adaptation mechanism contributing to emergence of CRPC. The work defines a potentially significant new targeting platform for overcoming therapeutic resistance in CRPC. (Endocrinology 158: 1612(Endocrinology 158: -1622(Endocrinology 158: , 2017 I n 2016, there will be .180,000 new cases of prostate cancer in the United States alone, accounting for more than one in five new cancer diagnoses and making this malignancy a leading cause of cancer deaths (1). Men with prostate cancer display a wide spectrum of clinical trajectories and biochemical outcomes, with most patients rapidly developing lethal disease. Our understanding of the use of systemic therapies to inhibit prostate tumor growth stems from the seminal discovery of Huggins and Hodges (2) on the inhibitory effects of castration-induced androgen depletion. Since that historic discovery in the 1940s, although we have amassed more knowledge on the intricacies of androgen signaling and the androgen receptor (AR), the treatment paradigm for recurrent prostate cancer, as well as an adjuvant to localized prostate cancer, relies on androgen deprivation Abbreviations: ADT, androgen deprivation therapy; AR, androgen receptor; CRPC, castration-resistant prostate cancer; DNTGFbRII, dominant-negative transforming growth factor-b receptor II; EMT, epithelial-mesenchymal transition; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; mCRPC, metastatic castration-resistant prostate cancer; mRNA, messenger RNA; PCR, polymerase chain reaction; RT-PCR, real-time reverse transcription polymerase chain reaction; SEM, standard error of the mean; TGF-b, transforming growth factor-b; TMPRSS2, transmembrane protease serine 2; TRAMP, transgenic adenocarcinoma of mouse prostate; TUNEL, terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling; WT, wild-type.
I n 2016, there will be .180,000 new cases of prostate cancer in the United States alone, accounting for more than one in five new cancer diagnoses and making this malignancy a leading cause of cancer deaths (1) . Men with prostate cancer display a wide spectrum of clinical trajectories and biochemical outcomes, with most patients rapidly developing lethal disease. Our understanding of the use of systemic therapies to inhibit prostate tumor growth stems from the seminal discovery of Huggins and Hodges (2) on the inhibitory effects of castration-induced androgen depletion. Since that historic discovery in the 1940s, although we have amassed more knowledge on the intricacies of androgen signaling and the androgen receptor (AR), the treatment paradigm for recurrent prostate cancer, as well as an adjuvant to localized prostate cancer, relies on androgen deprivation therapy (ADT) (2, 3) . This strategy aimed at abrogating AR-mediated growth, invariably leads to emergence of castration-resistant prostate cancer (CRPC) and patient lethality (4) . Targeting the androgen signaling (antiandrogens) and microtubules (taxane chemotherapy) has survival benefits in patients with metastatic castrationresistant prostate cancer (mCRPC), but therapeutic resistance develops, resulting in lethal disease (5) (6) (7) . The mechanism driving this resistance has been attributed to the addiction of CRPC cells to AR signaling and constitutively active AR splice variants (8) (9) (10) . Overriding the therapeutic resistance to antiandrogens and taxane chemotherapy in advanced prostate cancer requires understanding of additional mechanisms besides the functional involvement of AR and its variants (10) (11) (12) , as well as the contribution of the tumor microenvironment (13) . Indeed, recent evidence established that therapeutic inhibition of oncogenic drivers induces dramatic secretome changes, enabling a tumor microenvironment that nurtures expansion of resistant clones (13) .
The massive heterogeneity and plasticity that characterize prostate tumors critically point to the regulatory phenotypic changes in individual cells imposed by the microenvironment as contributors to metastasis and therapeutic resistance (14) . Perturbation of epithelial homeostasis via epithelial-mesenchymal transition (EMT) renders a critical venue for prostate tumor epithelial cells to become invasive and rapidly metastasize (14, 15) . During progression to metastasis, prostate cancer cells upon losing their epithelial features acquire invasive properties and undergo phenotypic EMT via engaging interactions from transforming growth factor-b (TGF-b) and the AR (3, 14, 15) . Previous studies from this laboratory established that functional exchanges between TGF-b signaling and androgens/AR determine prostate tumor growth, invasion, and metastasis via selective effects on apoptosis, EMT, and actin cytoskeleton remodeling (15, 16) . Moreover, a TGF-b cross-talk with the androgen axis potentially contributes to the functional switch of TGF-b from a tumor suppressor to metastases promoter in vitro and in in vivo preclinical models of prostate tumor progression (17, 18) .
EMT and actin cytoskeleton remodeling endow migratory properties among prostate tumor epithelial cells, allowing for their escape and invasion in the tumor microenvironment in response to TGF-b (14, 17, 19, 20) . Loss of E-cadherin expression and overexpression of N-cadherin in prostate cancer correlate with tumor grade and recurrence after surgery, functionally linking EMT to aggressive clinical behavior in advanced disease (21) (22) (23) (24) . We previously reported that introduction of the dominantnegative mutant transforming growth factor-b type II receptor (DNTGFbRII) in the prostate epithelium of transgenic adenocarcinoma of the prostate (TRAMP) mice accelerated prostate cancer progression via phenotypic effects on EMT (17) . In the present study, we used this in vivo model of prostate tumorigenesis to investigate the impact of a disrupted TGF-b receptor signaling on growth kinetics and EMT landscape, under conditions of castrate androgen levels. Our findings demonstrate that castrationinduced ADT led to prostate cancer cell apoptosis and loss of AR in tumors from TGFbRII wild-type (WT) mice, whereas in DNTGFbRII-derived prostate tumors, there was high proliferative activity and nuclear localization of AR (ligand-independent) and b-catenin. This study suggests that aberrant TGF-b signaling can drive CRPC via AR and Wnt/b-catenin signaling as an adaptation mechanism to castrate androgen levels toward CRPC.
Materials and Methods

Mouse model of prostate tumor progression
Mice were maintained under environmentally controlled conditions and subject to a 12-hour light/12-hour dark cycle with food and water ad libitum. The TRAMP mouse model [C57BL/6-Tg(TRAMP)8247Ng/J; The Jackson Laboratory, Bar Harbor, ME; stock no. 003135] is a well-characterized model of prostate cancer progression to metastasis. The DNTGFbRII mice were obtained from Dr. Lalage Wakefield (National Cancer Institute, Bethesda, MD). We have previously generated TRAMP DNTGFbRII mice in the C57BL/6 background (17, 25) . The TRAMP DNTGFbRII transgenic mice develop prostate adenocarcinoma earlier, with the malignant phenotype histopathologically evident at 12 weeks compared with age-matched TRAMP TGFbRII WT mice (17) . At 16 weeks TRAMP DNTGFbRII developed neuroendocrine type adenocarcinoma with local invasion. Because we previously reported (possibly due to high endogenous levels of zinc in prostate tumors) there was sufficient expression of the DNTGFbRII transgene in the TRAMP DNTGFbRII mice without ZnSO 4 in drinking water (17) , there was no treatment with zinc sulfate initiated in any of the mice in this study. All procedures and animal handling techniques were approved by the University of Kentucky Institutional Animal Care and Use Committee.
Surgical castration
Prior to the surgical procedure, mice were anesthetized with ketamine/xylazine (100 mg/kg ketamine plus 10 mg/kg xylazine in sterile saline (intraperitoneally). Prostate specimens were prepared after 48 hours of castration-induced ADT because it was established that during the period 2 to 3 days postcastration ADT causes a maximum rate of apoptosis in androgendependent prostate tumors (26) . Experimental groups are stratified as follows (n = 3 to 5 per group): (1) 
Apoptosis detection
The incidence of apoptosis was evaluated in situ using the terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling (TUNEL) assay (Millipore, Billerica, MA). Prostate tissue sections were counterstained with methyl green and TUNELpositive cells were counted per high-power field (40 3 10). Quantitative analysis of apoptosis was conducted as previously described (17, 27) . Numerical values represent the average number of positive cells counted from three different fields per section.
Immunohistochemical analysis
Tissue specimens from transgenic mouse prostate tumors were formalin fixed and paraffin embedded; serial sections (5 mm) subjected to immunohistochemical analysis using rabbit monoclonal antibodies against b-catenin and E-cadherin were obtained from Cell Signaling Technology (Danvers, MA); rabbit polyclonal antibodies against nuclear antigen, Ki-67 (cell proliferation marker), and N-cadherin were from Abcam; and rabbit polyclonal antibody against AR was obtained from Santa Cruz Biotechnology (Santa Cruz, CA) (for antibodies used in this study, see Table 1 ). Sections exposed to specific primary antibody and immunostaining were detected by biotinylated goat anti-rabbit IgG and horseradish peroxidase-streptavidin conjugate (Millipore). Color development was performed using a SIGMAFAST 3,3 0 -diaminobenzidine-based kit (SigmaAldrich, St. Louis, MO) and counterstained with hematoxylin. Images were captured with an Olympus BX51 microscope (Olympus America, Center Valley, PA). Ki-67 average numbers of positive cells were counted from three fields per section.
Western blotting
Protein samples were prepared using the NE-PER nuclear and cytoplasmic fraction kit (Thermo Scientific, Rockford, IL). Protein content was quantified using Pierce BCA protein assay kits (Thermo Scientific), and protein samples were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (4% to 15% sodium dodecyl sulfate-polyacrylamide gels; Bio-Rad Laboratories, Hercules, CA) and transferred to Hybond-C membranes (Amersham Pharmacia Biotech, Piscataway, NJ). Membranes were blocked in 5% milk in Tris-buffered saline containing 0.05% Tween 20, and following incubation with the respective primary antibody (overnight at 4°C), membranes were exposed to species-specific horseradish peroxidaselabeled secondary antibody (Jackson ImmunoResearch Laboratories, West Grove, PA). Signal detection was achieved with HyGLO quick spray chemiluminescent horseradish peroxidase antibody detection reagent (Denville Scientific, Metuchen, NJ). Protein expression was determined by using the same antibodies as for immunohistochemical analysis and specific rabbit polyclonal antibodies against Smad4 (Abcam), as well as mouse monoclonal Bcl-2 antibody (Santa Cruz Biotechnology). Whole and cytoplasmic protein levels were normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression, using the rabbit monoclonal antibodies against GAPDH (Cell Signaling Technology). Nuclear protein expression was normalized to histone H3 antibody (Cell Signaling Technology).
Quantitative real-time reverse transcription polymerase chain reaction analysis Molecular profiling was conducted using real-time polymerase chain reaction (PCR) analysis of prostate tumors from intact and castrated mice (48 hours). Total RNA was extracted from prostate tissue using TRIzol reagent (Invitrogen/Life Technologies) and was subjected (1 mg) to reverse transcription into complementary DNA using a reverse transcription kit from Promega (Madison, WI) under the following conditions: 25°C for 10 minutes, 42°C for 60 minutes, and 95°C for 5 minutes. Primer pairs and TaqMan probes (Applied Biosystems, Foster City, CA) were used to determine AR (Mm00442688_m1), b-catenin (Mm00483039_m1), E-cadherin (Mm01247357_m1), and Ncadherin (Mm00483213_m1) gene expression. Primer pairs to assess transmembrane protease serine 2 (TMPRSS2), Smad4, Twist-1, and ZEB-1 messenger RNA (mRNA) expression were designed using Primer Express software (Applied Biosystems, Branchburg, NJ). The following primers were used: Smad4, forward, 5
0 . Real-time PCR was conducted in an ABI Prism 7300 system (Applied Biosystems, Branchburg, NJ) in TaqMan Fast universal PCR master mix (Life Technologies, Austin, TX) and Power SYBR Green PCR master mix (Life Technologies, Woolston Warrington, UK). Numerical data (normalized to 18S mRNA and b-actin levels) indicate mean values 6 standard error of the mean (SEM; n = 4-6) (27) .
Statistical analysis
Numerical data were analyzed for statistical significance using the unpaired t test by GraphPad Prism 6. Values are expressed as the mean 6 SEM. Statistical differences were considered significant at a P value of ,0.05.
Results
Representative images of comparative assessment of cell proliferation and apoptosis incidence in serial sections of prostate tumors derived from 20-week-old TGFbRII WT and DNTGFbRII mice after castration (48 hours) are shown in Fig. 1(a) . Quantitative analysis of Ki-67 immunoreactivity among the prostate tumor epithelial cells revealed a higher proliferative index in prostate tumors from DNTGFbRII mice compared with TGFbRII WT mice [ Fig. 1 (a) and 1(b), P , 0.05]. Assessment of the number of apoptotic (TUNEL-positive) cells among the prostate tumor cell populations after castration-induced ADT revealed no significant change in the incidence of apoptosis between the two groups [ Fig. 1(a) (subpanels c and d) and 1(b)]. There was, however, a significant reduction in the apoptosis to cell proliferation ratio in prostate tumors from DNTGFbRII mice compared with TGFbRII WT mice [ Fig. 1(a) and 1(b) ]. Western protein analysis of bcl-2 expression (an apoptosis suppressor) in prostate tumors showed a marked increase in bcl-2 protein levels in DNTGFbRII-derived prostate tumors compared with TGFbRII WT after castration [ Fig. 1(c) ].
We subsequently investigated the consequences of aberrant TGF-b signaling on AR expression and cellular localization in prostate tumor tissue from castrate TGFbRRII WT and DNTGFbRII (age-matched mice). , quantitative analysis shows no significant difference in the number of apoptotic cells between the two groups; however, the apoptosis/proliferation ratio was significantly lower after castration in prostate tumors from the DNTTGFbRII genotype compared with TGFbRII WT mice. **P , 0.001. (c) Western blot analysis of bcl-2 protein expression in prostate tumor lysates from castrate TGFbTRII WT and DN TGFbTRII mice. Increased bcl-2 levels were detected; tumors from the latter were compared with WT. GAPDH was used as a loading control.
TMPRSS2 was selected as a target gene for the AR action in prostate cancer, as it is established that this gene is ARdriven/upregulated by androgens in androgen-dependent human prostate cancer and downregulated in androgenindependent tumors (28) . The encoded protein contains a type II transmembrane domain, a receptor class A domain, a scavenger receptor cysteine-rich domain, and a protease domain. Real-time reverse transcription polymerase chain reaction (RT-PCR) analysis revealed a significant decrease in gene expression for both AR and TMPRSS2 in TGFbRRII WT in response to castrationinduced ADT. In contrast, there was a significant induction of AR mRNA expression and AR transcriptional activity (TMPRSS2 gene) (P , 0.005) in prostate tumors from DNTGFbRII after castration, compared with intact mice Tumors derived from castrated TGFbRII WT mice exhibited a marked depletion of nuclear AR among prostate tumor acini compared with tumors from intact mice [ Fig. 2(c) ]. In contrast to tumors from castrate TGFbRII WT, there was marked increased AR nuclear localization among prostate glandular epithelial cells in castrate DNTGFbRII mice [ Fig. 2(c) ]. Comparative analysis of AR mRNA expression in prostate tumors from TGFbRII WT and DNTGFbRII mice after castration revealed a significant difference in the levels of both AR and TMPRSS2 mRNA between the two groups (P , 0.005), with a significant upregulation of both genes in prostate tumors from DNTGFbRII castrate mice [ Fig. 2 (e) and 2(f); P , 0.001]. Western blot analysis of the subcellular distribution of AR protein revealed that in TGFbRII WT mice ADT resulted in a marked reduction in AR protein levels in both the cytoplasmic and nuclear fractions of prostate tumors (Supplemental Fig. 1 ). Similarly in tumors from DNTGFbRII mice, there was depletion of both cytoplasmic and nuclear AR protein levels in response to ADT; nuclear AR presence was still detected in castrate DNTGFbRII tumor lysates (Supplemental Fig. 1) .
The effect of ADT on Smad4 mRNA and protein expression and localization was then investigated in prostate tumors from TGFbRII WT and DNTGFbRII mice before and after castration-induced ADT. As shown on Fig. 3(a) , an increase in Smad4 mRNA expression in castrate DNTGFbRII tumors compared with TGFbRII WT was not statistically significant. Examination of the subcellular localization of Smad4 protein revealed higher Smad4 levels in both cytoplasmic and nuclear fractions in prostate tumors from the DNTGFbRII mice compared with prostate tumor lysates from TGFbRII WT mice [ Fig. 3(b) ]. Castration-induced ADT resulted in a significant increase in Smad4 mRNA expression in tumors harboring the DNTGFbRII genotype, but not in TGFbRII WT-derived tumors [ Fig. 3(c) ]. Because ADT causes increased Smad4 in the context of activated TGF-b signaling potentially inducing EMT, we examined the mRNA expression of two transcriptional activators of EMT, ZEB-1, and Twist in TGFbRII WT and DNTGFbRII. Castration-induced ADT led to increased expression in ZEB1 and Twist in tumors from DNTGFbRII [ Fig. 3(d) ].
Considering that loss of epithelial cell markers (Ecadherin, b-catenin) and gain of mesenchymal markers (N-cadherin) at the invasive front of advanced prostate tumors drive EMT (17) , in subsequent experiments we conducted a comparative profiling of the EMT signature in prostate tumors from TGFbRII WT and DNTGFbRII mice after castration-induced ADT (48 hours). In response to castration-induced ADT, there was reduction in E-cadherin immunoreactivity in prostate tumors from TGFbRII WT, associated with a marked increase in Ncadherin immunoreactivity [ Fig. 4(a) ]. These changes that are reflective of EMT induction were validated by Western blot analysis of the two EMT characteristic effector proteins [ Fig. 4(b) ]. Prostate tumors from DNTGFbRII mice exhibited a decrease in E-cadherin protein levels after castration-induced ADT and a parallel increase in N-cadherin, but the changes were modest compared with TGFbRII WT-derived tumors, indicating a predominant epithelial phenotype [ Fig. 4(b)  and 4(d) ]. RT-PCR analysis of mRNA expression for the EMT effectors under intact and castrate conditions revealed a significant decrease in mRNA for E-cadherin and a parallel significant increase in N-cadherin mRNA in tumors from castrate TGFbRII WT relative to intact mice (P , 0.05) [ Fig. 4 (e) and 4(f)]. There was a significant increase in mRNA levels of E-cadherin in prostate tumors from DNTGFbRII after castration (P , 0.05), with no significant changes in N-cadherin mRNA in response to castration in these tumors [ Fig. 4(e) and 4(f) ].
In view of mechanistic evidence that AR can signal through Wnt/b-catenin by recruiting nuclear Wnt/ b-catenin under castrate androgen levels toward CRPC (29, 30), we subsequently investigated the effect of ADT on the expression and subcellular localization of b-catenin in prostate tumors from TGFbRII WT and DNTGFbRII mice. As shown in Fig. 5 , there was a marked increase in b-catenin protein in prostate tumors of castrate DNTGFbRII mice, compared with TGFbRII WT mice. Fig. 5(a) shows representative images of b-catenin immunoreactivity profile in prostate tumors from castrate DNTGFbRII and TGFbRII WT mice. An increase in b-catenin mRNA expression was detected in the DNTGFbRII-derived prostate tumors, but this failed to reach statistical significance [ Fig. 5(b) ]. The ADTinduced increase in nuclear b-catenin protein levels in prostate tumors from DNTGFbRII mice was also detected by comparative immunoblot analysis of prostate tumor lysates from TGFbRII WT and DNTGFbRII mice [ Fig. 5(c) and 5(d) ], confirming the immunostaining observations [ Fig. 5(a) ]. Analysis of the changes in b-catenin expression and subcellular localization in intact and castrate mice (48 hours) indicates no major changes in cytoplasmic or nuclear b-catenin in prostate tumors from TGFbRII WT after castration, whereas there was a marked increase in nuclear b-catenin in prostate tumors from DNTGFbRII after castration (Supplemental Fig. 2 ).
Discussion
Progression of human prostate cancer to metastasis is navigated by the androgen axis and diverse signaling pathways regulating apoptosis, EMT, and invasion of tumor epithelial cells (14) . AR is a critical determinant of therapeutic response in patients with mCRPC, and persistent AR signaling via elevated intratumoral androgens or AR splice variants confers therapeutic resistance to antiandrogens and taxane chemotherapy, leading to recurrent disease (8, 12, 31) . In the present study using our preclinical model of EMT-driven prostate cancer progression (17), we define a new role for TGF-b signaling as a driver of ligand-independent activation of AR (under conditions of ADT) to castration-resistant state in prostate tumors. After castration-induced androgen depletion, there was a significantly increased cell proliferative index in tumors derived from DNTGFbRII mice that was associated with a low apoptosis to cell proliferation ratio; this loss of apoptosis control is potentially driven by bcl-2 overexpression, the apoptosis suppressor implicated in the clinical development of CRPC (32) . In contrast, there was an elevated apoptosis to proliferation ratio in tumors derived from TGFbRII WT mice, indicating a higher growth activity among the prostate tumor cell populations in DNTGFbRII despite castrate androgen levels.
The significant upregulation of AR and TMPRSS2 mRNA expression (induced AR gene transcription) in prostate tumors from DNTGFbRII was significantly distinct from the effect observed in TGFbRII WT mice. Tumors from DNTGFbRII mice sustained AR nuclear localization after castration-induced androgen depletion that temporally correlated with increased AR mRNA expression and activity; in contrast, TGFbRII WT-derived tumors had depleted nuclear AR among androgen-dependent acini after ADT. Therefore, our present findings suggest that TGF-b signaling serving as an upstream mechanism functionally contributes to therapeutic resistance to antiandrogens/ADT by sustaining AR expression and activity after ADT. The concept that AR is not the exclusive driver of therapeutic response in CRPC gains support from evidence that TGF-b signaling of apoptosis and EMT during prostate tumorigenesis can be compromised via negative regulation of AR transcriptional activity (33) .
Coordinated molecular events engendering phenotypic alterations in the tumor landscape result in acquisition of mesenchymal traits by tumor epithelial cells. Loss of E-cadherin expression and overexpression of Ncadherin in prostate cancer correlate with high tumor grade, metastasis, and disease recurrence, linking EMT to aggressive clinical behavior (23, 24) . Evidence in preclinical models of CRPC established that EMT is influenced by the androgen signaling axis, impacting metastatic progression and therapeutic resistance (23, 25) . The increased cell proliferative capacity (with no significant changes in apoptosis) in prostate tumors from DNTGFbRII may provide an explanation for the predominant epithelial phenotype detected in the tumor EMT landscape after ADT. Moreover, the documented increase in b-catenin levels in both cytoplasmic and nuclear fractions in response to ADT points to Wnt pathway activation under aberrant TGF-b signaling. Nuclear localization of b-catenin has been previously associated with prostate tumorigenic growth via AR transcriptional activation, and TGF-b1 action in CRPC requires nuclear distribution of b-catenin (29, 30, 33) . Our present findings taken together with this evidence support the engagement of Wnt/b-catenin signaling by the TGF-b network as an adaptation mechanism of prostate cancer cells to castrate androgen levels, ultimately contributing to the emergence of CRPC.
Considering that the long-standing challenge in the treatment of CRPC is to overcome therapeutic resistance during progression to lethal disease, defining the molecular events through which TGF-b in the tumor microenvironment contributes to emergence of mCRPC is of major translational significance in overcoming resistance to ADT in CRPC. These results implicate the potential therapeutic value of targeting TGF-b signaling under castrate androgen levels for patients with advanced CRPC. In addition to the phenotypic "identity shift" in prostate tumors in response to ADT treatment proceeding via EMT interconversion to mesenchymal-epithelial transition (27) , other TGF-b-navigated events in the microenvironment may contribute to therapeutic resistance. The involvement of cofilin, a TGF-b signaling effector and regulator of actin cytoskeleton polymerization and remodeling, in CRPC is being investigated in our preclinical model in response to androgen depletion and TGF-b blockade (18) . Compelling evidence has linked diverse molecular mechanisms to nuclear accumulation and activation of AR in the absence of androgens (toward castrate-resistant disease), including ZEB transcription factors engaged by nuclear import and export signals facilitating EMT (34), recruitment of lysinespecific demethylase 1 (35) , steroid receptor coactivators directed by TGF-b (36, 37) , and integrin a v b 6 -mediated JNK1 activation (38) .
In summary, our study supports the development of TGF-b-targeted therapies to overcome therapeutic resistance to antiandrogen therapy, bypassing the "classic" AR addiction as well as the clinically relevant AR variants (27, 39) in patients with advanced mCRPC (40) . Ongoing studies on the impact on survival in the preclinical model will pave the way for clinical development in improving therapeutic modalities for lethal metastatic disease.
